Observing kidney issues in children with tuberous sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the prevalence of renal involvement, specifically angiomyolipomas and renal cysts, in pediatric patients diagnosed with tuberous sclerosis complex (TSC). It is a retrospective, multicenter, nonprofit study that evaluates clinical data from patients under 17 years of age who were diagnosed with TSC between January 1, 2018, and June 30, 2021. The study seeks to fill the gap in literature regarding renal complications in this population, which can lead to severe health issues, including chronic kidney disease and increased risk of renal carcinoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients of either sex under the age of 17 years at the time of last observation (06/30/2021);
* Patients clinically evaluated in an outpatient or inpatient setting during 01/01/2018- 30/06/2021 with a diagnosis of TSC;
* Informed consent signed by parent or legal guardian.

Exclusion Criteria:

* Patients older than 18 years of age;
* Patients with other phacomatoses.

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Italy Recruiting

Study contacts

• Principal investigator: Andrea Pasini, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Andrea Pasini, MD
• Email: andrea.pasini@aosp.bo.it
• Phone: 00390512144613

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Periodontal Health in Rare Kidney Conditions and Controls

  This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.

  Recruiting Institutul Clinic Fundeni · Bucharest · NCT07575347

• Full‑spectrum cannabis extract for refractory epilepsy in tuberous sclerosis

  This trial tests whether a full‑spectrum cannabis extract (YCJ-01) can reduce seizures in people with tuberous sclerosis complex who have hard‑to‑control epilepsy.

  Recruiting Phase 3 Oils4Cure · Madrid · NCT07403266

• Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors

  This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.

  Recruiting Phase 1 Sapu Nano (Us) LLC · Adelaide · NCT07369505

• Paxalisib added to treat certain brain conditions with seizures

  This study tests whether Paxalisib (SVG103) is safe and tolerable in adults with FCD-II, TSC, or HME who have frequent seizures.

  Recruiting at 2 sites Phase 1/2 Sovargen · Heidelberg, Victoria and 1 other locations · NCT07287202

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.